Castration-resistant Prostate Cancer Clinical Trials

139 recruitingLast updated: June 17, 2026

There are 139 actively recruiting castration-resistant prostate cancer clinical trials across 51 countries. Studies span Phase 1, Phase 2, Phase 3, Early Phase 1, Not Applicable, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Castration-resistant Prostate Cancer Trials at a Glance

139 actively recruiting trials for castration-resistant prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 1 with 67 trials, with the heaviest enrollment activity in Houston, New York, and San Francisco. Lead sponsors running castration-resistant prostate cancer studies include Novartis Pharmaceuticals, AstraZeneca, and Astellas Pharma Global Development, Inc..

Browse castration-resistant prostate cancer trials by phase

Treatments under study

About Castration-resistant Prostate Cancer Clinical Trials

Looking for clinical trials for Castration-resistant Prostate Cancer? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Castration-resistant Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Castration-resistant Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 139 trials

Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 4

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer
Bayer50 enrolled25 locationsNCT05348876
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 1

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen40 enrolled3 locationsNCT07493512
Recruiting
Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled5 locationsNCT06844383
Recruiting
Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled134 locationsNCT07213674
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07641049
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Pathos AI, Inc.120 enrolled18 locationsNCT06785636
Recruiting
Phase 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Hoffmann-La Roche100 enrolled32 locationsNCT07287150
Recruiting
Phase 1Phase 2

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.190 enrolled9 locationsNCT07285694
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Advanced Metastatic Castration-resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.84 enrolled22 locationsNCT06609005
Recruiting

PRostate Olaparib Real World Evidence Study

Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805
Recruiting
Phase 1

A Phase I Trial of A-CAR032 in Participants With mCRPC

Prostate CancerMetastatic Castration-resistant Prostate Cancer
Shanghai AbelZeta Ltd.27 enrolled5 locationsNCT07344311
Recruiting
Phase 2

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Syntrix Biosystems, Inc.53 enrolled6 locationsNCT06228053
Recruiting
Phase 1

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Metastatic Castration-resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital12 enrolled2 locationsNCT07621692
Recruiting

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals500 enrolled37 locationsNCT06517719